Azelastine Nasal Spray in Non-Hospitalized Subjects with Mild COVID-19 Infection: A Randomized Placebo-Controlled, Parallel-Group, Multicentric, Phase II Clinical Trial.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Nasal Sprays* ; Viral Load*/drug effects ; Phthalazines*/administration & dosage ; Phthalazines*/therapeutic use ; SARS-CoV-2*/drug effects ; COVID-19*/virology ; COVID-19 Drug Treatment*; Humans ; Male ; Female ; Middle Aged ; Adult ; Double-Blind Method ; Prospective Studies ; Hospitalization ; Antiviral Agents/administration & dosage ; Antiviral Agents/therapeutic use ; Administration, Intranasal ; Treatment Outcome ; Aged ; Nasopharynx/virology

Nasal spray treatments that inhibit the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) entry into nose and nasopharynx at early stages can be an appropriate approach to stop or delay the progression of the disease. We performed a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicentric, phase II clinical trial comparing the rate of hospitalization due to COVID-19 infection between azelastine 0.1% nasal spray and placebo nasal spray treatment groups. The study furthermore assessed the reduction in virus load in SARS-CoV-2-infected subjects estimated via quantitative reverse transcriptase polymerase chain reaction (RT-PCR) using nasopharyngeal swabs in both groups during the treatment period. A total of 294 subjects with mild COVID-19 infection were screened and randomized in a 1:1 ratio. There was no incidence of COVID-19-related hospitalization in either treatment group. Mean virus load was significantly reduced in both groups during the 11 treatment days as compared with baseline viral load values. The reduction in virus load in the azelastine 0.1% nasal spray group was significantly higher than the reduction in the placebo group at day 11 (log 10 5.93 vs. log 10 5.85 copies/mL, respectively, p = 0.0041). A total of 39 (32.0%) subjects in the azelastine 0.1% treatment group and 40 (31.0%) subjects in the placebo group reported 48 and 51 adverse events, respectively. It is therefore concluded that azelastine 0.1% nasal spray is an efficacious, safe, and well-tolerated treatment of mild COVID-19 infection.

Expert Rev Anti Infect Ther. 2021 Oct;19(10):1325-1330. (PMID: 33759682)
Acta Pharmacol Sin. 2021 Aug;42(8):1347-1353. (PMID: 33116249)
Sci Rep. 2023 Apr 26;13(1):6839. (PMID: 37100830)
N Engl J Med. 2022 Feb 10;386(6):509-520. (PMID: 34914868)
Biochem Biophys Res Commun. 2021 Jan 29;538:173-179. (PMID: 33309272)
Cureus. 2022 Nov 14;14(11):e31508. (PMID: 36532902)
Nat Med. 2022 May;28(5):1031-1041. (PMID: 35361992)
Lancet Reg Health Southeast Asia. 2022 Aug;3:100036. (PMID: 35784831)
Struct Chem. 2020;31(6):2487-2499. (PMID: 32837119)
Pharmaceutics. 2022 Sep 27;14(10):. (PMID: 36297492)
Postgrad Med J. 2021 May;97(1147):312-320. (PMID: 32978337)
ACS Med Chem Lett. 2020 Oct 25;11(12):2526-2533. (PMID: 33324471)
Elife. 2021 Sep 27;10:. (PMID: 34569939)
J Infect. 2021 Aug;83(2):237-279. (PMID: 33992687)
Bioinformation. 2020 Mar 31;16(3):236-244. (PMID: 32308266)
Sci Rep. 2024 Jan 2;14(1):220. (PMID: 38167962)
Front Pharmacol. 2022 Jun 30;13:861295. (PMID: 35846988)
Virol J. 2023 Feb 8;20(1):23. (PMID: 36755327)
Viruses. 2023 Nov 23;15(12):. (PMID: 38140540)

Keywords: COVID-19; COVID-19 related hospitalization; SARS-CoV-2; azelastine; clinical trial; nasal spray; viral load

CTRI CTRI/2022/09/

ZQI909440X (azelastine)
0 (Nasal Sprays)
0 (Phthalazines)
0 (Antiviral Agents)

Date Created: 20250108 Date Completed: 20250108 Latest Revision: 20250414

20250415

PMC11680327

10.3390/v16121914

39772221